mouse prostate cancer cells Search Results


mouse neuroendocrine prostate cancer pnec30 cells  (Charles River Laboratories)
90
Charles River Laboratories mouse neuroendocrine prostate cancer pnec30 cells
(A and B) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing 4T1 mouse triple-negative breast tumor cells. (A) Scheme of treatments. (B) Overall survival data for the four groups of mice with different treatments (n = 8 or 10). (C and D) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing EMT6 mouse triple-negative breast tumor cells. (C) Growth of primary tumors. Data are presented as mean ± SEM (n = 8 or 9). (D) Overall survival data for the four groups of mice with different treatments (n = 8 or 9). (E) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing LLC mouse lung cancer cells (n = 8–10). (F) Fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing Pan02 mouse pancreatic cancer cells (n = 7 or 8). (G) NP-G2–044 with anti-PD-1 and anti-CTLA-4 antibodies increase the overall survival of mice bearing <t>PNEC30</t> mouse prostate cancer cells (n = 8 or 9).
Mouse Neuroendocrine Prostate Cancer Pnec30 Cells, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse neuroendocrine prostate cancer pnec30 cells/product/Charles River Laboratories
Average 90 stars, based on 1 article reviews
mouse neuroendocrine prostate cancer pnec30 cells - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
mouse prostate cancer cells rm-1  (iCell Bioscience Inc)
90
iCell Bioscience Inc mouse prostate cancer cells rm-1
(A and B) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing 4T1 mouse triple-negative breast tumor cells. (A) Scheme of treatments. (B) Overall survival data for the four groups of mice with different treatments (n = 8 or 10). (C and D) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing EMT6 mouse triple-negative breast tumor cells. (C) Growth of primary tumors. Data are presented as mean ± SEM (n = 8 or 9). (D) Overall survival data for the four groups of mice with different treatments (n = 8 or 9). (E) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing LLC mouse lung cancer cells (n = 8–10). (F) Fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing Pan02 mouse pancreatic cancer cells (n = 7 or 8). (G) NP-G2–044 with anti-PD-1 and anti-CTLA-4 antibodies increase the overall survival of mice bearing <t>PNEC30</t> mouse prostate cancer cells (n = 8 or 9).
Mouse Prostate Cancer Cells Rm 1, supplied by iCell Bioscience Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse prostate cancer cells rm-1/product/iCell Bioscience Inc
Average 90 stars, based on 1 article reviews
mouse prostate cancer cells rm-1 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
mouse prostate cancer cell line rm-1  (China Center for Type Culture Collection)
90
China Center for Type Culture Collection mouse prostate cancer cell line rm-1
(A and B) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing 4T1 mouse triple-negative breast tumor cells. (A) Scheme of treatments. (B) Overall survival data for the four groups of mice with different treatments (n = 8 or 10). (C and D) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing EMT6 mouse triple-negative breast tumor cells. (C) Growth of primary tumors. Data are presented as mean ± SEM (n = 8 or 9). (D) Overall survival data for the four groups of mice with different treatments (n = 8 or 9). (E) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing LLC mouse lung cancer cells (n = 8–10). (F) Fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing Pan02 mouse pancreatic cancer cells (n = 7 or 8). (G) NP-G2–044 with anti-PD-1 and anti-CTLA-4 antibodies increase the overall survival of mice bearing <t>PNEC30</t> mouse prostate cancer cells (n = 8 or 9).
Mouse Prostate Cancer Cell Line Rm 1, supplied by China Center for Type Culture Collection, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse prostate cancer cell line rm-1/product/China Center for Type Culture Collection
Average 90 stars, based on 1 article reviews
mouse prostate cancer cell line rm-1 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
mouse prostate cancer cells 10 6 tc2r  (Taconic Biosciences)
90
Taconic Biosciences mouse prostate cancer cells 10 6 tc2r
(A and B) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing 4T1 mouse triple-negative breast tumor cells. (A) Scheme of treatments. (B) Overall survival data for the four groups of mice with different treatments (n = 8 or 10). (C and D) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing EMT6 mouse triple-negative breast tumor cells. (C) Growth of primary tumors. Data are presented as mean ± SEM (n = 8 or 9). (D) Overall survival data for the four groups of mice with different treatments (n = 8 or 9). (E) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing LLC mouse lung cancer cells (n = 8–10). (F) Fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing Pan02 mouse pancreatic cancer cells (n = 7 or 8). (G) NP-G2–044 with anti-PD-1 and anti-CTLA-4 antibodies increase the overall survival of mice bearing <t>PNEC30</t> mouse prostate cancer cells (n = 8 or 9).
Mouse Prostate Cancer Cells 10 6 Tc2r, supplied by Taconic Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse prostate cancer cells 10 6 tc2r/product/Taconic Biosciences
Average 90 stars, based on 1 article reviews
mouse prostate cancer cells 10 6 tc2r - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
prostate cancer cell line hucell psma-rm1  (Crown Bioscience)
90
Crown Bioscience prostate cancer cell line hucell psma-rm1
(A and B) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing 4T1 mouse triple-negative breast tumor cells. (A) Scheme of treatments. (B) Overall survival data for the four groups of mice with different treatments (n = 8 or 10). (C and D) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing EMT6 mouse triple-negative breast tumor cells. (C) Growth of primary tumors. Data are presented as mean ± SEM (n = 8 or 9). (D) Overall survival data for the four groups of mice with different treatments (n = 8 or 9). (E) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing LLC mouse lung cancer cells (n = 8–10). (F) Fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing Pan02 mouse pancreatic cancer cells (n = 7 or 8). (G) NP-G2–044 with anti-PD-1 and anti-CTLA-4 antibodies increase the overall survival of mice bearing <t>PNEC30</t> mouse prostate cancer cells (n = 8 or 9).
Prostate Cancer Cell Line Hucell Psma Rm1, supplied by Crown Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prostate cancer cell line hucell psma-rm1/product/Crown Bioscience
Average 90 stars, based on 1 article reviews
prostate cancer cell line hucell psma-rm1 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
prostate pten-mutant mouse prostate cancer cell  (Bioscientifica Ltd)
90
Bioscientifica Ltd prostate pten-mutant mouse prostate cancer cell
(A and B) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing 4T1 mouse triple-negative breast tumor cells. (A) Scheme of treatments. (B) Overall survival data for the four groups of mice with different treatments (n = 8 or 10). (C and D) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing EMT6 mouse triple-negative breast tumor cells. (C) Growth of primary tumors. Data are presented as mean ± SEM (n = 8 or 9). (D) Overall survival data for the four groups of mice with different treatments (n = 8 or 9). (E) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing LLC mouse lung cancer cells (n = 8–10). (F) Fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing Pan02 mouse pancreatic cancer cells (n = 7 or 8). (G) NP-G2–044 with anti-PD-1 and anti-CTLA-4 antibodies increase the overall survival of mice bearing <t>PNEC30</t> mouse prostate cancer cells (n = 8 or 9).
Prostate Pten Mutant Mouse Prostate Cancer Cell, supplied by Bioscientifica Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prostate pten-mutant mouse prostate cancer cell/product/Bioscientifica Ltd
Average 90 stars, based on 1 article reviews
prostate pten-mutant mouse prostate cancer cell - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
mouse prostate cancer cell line rm-1  (Shanghai Genechem Ltd)
90
Shanghai Genechem Ltd mouse prostate cancer cell line rm-1
(A and B) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing 4T1 mouse triple-negative breast tumor cells. (A) Scheme of treatments. (B) Overall survival data for the four groups of mice with different treatments (n = 8 or 10). (C and D) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing EMT6 mouse triple-negative breast tumor cells. (C) Growth of primary tumors. Data are presented as mean ± SEM (n = 8 or 9). (D) Overall survival data for the four groups of mice with different treatments (n = 8 or 9). (E) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing LLC mouse lung cancer cells (n = 8–10). (F) Fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing Pan02 mouse pancreatic cancer cells (n = 7 or 8). (G) NP-G2–044 with anti-PD-1 and anti-CTLA-4 antibodies increase the overall survival of mice bearing <t>PNEC30</t> mouse prostate cancer cells (n = 8 or 9).
Mouse Prostate Cancer Cell Line Rm 1, supplied by Shanghai Genechem Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse prostate cancer cell line rm-1/product/Shanghai Genechem Ltd
Average 90 stars, based on 1 article reviews
mouse prostate cancer cell line rm-1 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
mouse rm-1-bm prostate cancer cells  (Jackson Laboratory)
90
Jackson Laboratory mouse rm-1-bm prostate cancer cells
(A and B) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing 4T1 mouse triple-negative breast tumor cells. (A) Scheme of treatments. (B) Overall survival data for the four groups of mice with different treatments (n = 8 or 10). (C and D) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing EMT6 mouse triple-negative breast tumor cells. (C) Growth of primary tumors. Data are presented as mean ± SEM (n = 8 or 9). (D) Overall survival data for the four groups of mice with different treatments (n = 8 or 9). (E) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing LLC mouse lung cancer cells (n = 8–10). (F) Fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing Pan02 mouse pancreatic cancer cells (n = 7 or 8). (G) NP-G2–044 with anti-PD-1 and anti-CTLA-4 antibodies increase the overall survival of mice bearing <t>PNEC30</t> mouse prostate cancer cells (n = 8 or 9).
Mouse Rm 1 Bm Prostate Cancer Cells, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse rm-1-bm prostate cancer cells/product/Jackson Laboratory
Average 90 stars, based on 1 article reviews
mouse rm-1-bm prostate cancer cells - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
mouse prostate cancer rm-1 cells  (Procell Inc)
90
Procell Inc mouse prostate cancer rm-1 cells
(A and B) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing 4T1 mouse triple-negative breast tumor cells. (A) Scheme of treatments. (B) Overall survival data for the four groups of mice with different treatments (n = 8 or 10). (C and D) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing EMT6 mouse triple-negative breast tumor cells. (C) Growth of primary tumors. Data are presented as mean ± SEM (n = 8 or 9). (D) Overall survival data for the four groups of mice with different treatments (n = 8 or 9). (E) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing LLC mouse lung cancer cells (n = 8–10). (F) Fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing Pan02 mouse pancreatic cancer cells (n = 7 or 8). (G) NP-G2–044 with anti-PD-1 and anti-CTLA-4 antibodies increase the overall survival of mice bearing <t>PNEC30</t> mouse prostate cancer cells (n = 8 or 9).
Mouse Prostate Cancer Rm 1 Cells, supplied by Procell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse prostate cancer rm-1 cells/product/Procell Inc
Average 90 stars, based on 1 article reviews
mouse prostate cancer rm-1 cells - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
mouse rm-9 prostate cancer cells  (Jackson Laboratory)
90
Jackson Laboratory mouse rm-9 prostate cancer cells
(A and B) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing 4T1 mouse triple-negative breast tumor cells. (A) Scheme of treatments. (B) Overall survival data for the four groups of mice with different treatments (n = 8 or 10). (C and D) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing EMT6 mouse triple-negative breast tumor cells. (C) Growth of primary tumors. Data are presented as mean ± SEM (n = 8 or 9). (D) Overall survival data for the four groups of mice with different treatments (n = 8 or 9). (E) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing LLC mouse lung cancer cells (n = 8–10). (F) Fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing Pan02 mouse pancreatic cancer cells (n = 7 or 8). (G) NP-G2–044 with anti-PD-1 and anti-CTLA-4 antibodies increase the overall survival of mice bearing <t>PNEC30</t> mouse prostate cancer cells (n = 8 or 9).
Mouse Rm 9 Prostate Cancer Cells, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse rm-9 prostate cancer cells/product/Jackson Laboratory
Average 90 stars, based on 1 article reviews
mouse rm-9 prostate cancer cells - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


(A and B) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing 4T1 mouse triple-negative breast tumor cells. (A) Scheme of treatments. (B) Overall survival data for the four groups of mice with different treatments (n = 8 or 10). (C and D) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing EMT6 mouse triple-negative breast tumor cells. (C) Growth of primary tumors. Data are presented as mean ± SEM (n = 8 or 9). (D) Overall survival data for the four groups of mice with different treatments (n = 8 or 9). (E) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing LLC mouse lung cancer cells (n = 8–10). (F) Fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing Pan02 mouse pancreatic cancer cells (n = 7 or 8). (G) NP-G2–044 with anti-PD-1 and anti-CTLA-4 antibodies increase the overall survival of mice bearing PNEC30 mouse prostate cancer cells (n = 8 or 9).

Journal: Cell reports

Article Title: Fascin inhibitor increases intratumoral dendritic cell activation and anti-cancer immunity

doi: 10.1016/j.celrep.2021.108948

Figure Lengend Snippet: (A and B) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing 4T1 mouse triple-negative breast tumor cells. (A) Scheme of treatments. (B) Overall survival data for the four groups of mice with different treatments (n = 8 or 10). (C and D) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing EMT6 mouse triple-negative breast tumor cells. (C) Growth of primary tumors. Data are presented as mean ± SEM (n = 8 or 9). (D) Overall survival data for the four groups of mice with different treatments (n = 8 or 9). (E) Combination treatments of fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing LLC mouse lung cancer cells (n = 8–10). (F) Fascin inhibitors with anti-PD-1 and anti-CTLA-4 antibodies synergistically increase the overall survival of mice bearing Pan02 mouse pancreatic cancer cells (n = 7 or 8). (G) NP-G2–044 with anti-PD-1 and anti-CTLA-4 antibodies increase the overall survival of mice bearing PNEC30 mouse prostate cancer cells (n = 8 or 9).

Article Snippet: Moreover, we also studied the mouse neuroendocrine prostate cancer PNEC30 cells that are resistant to ICI treatments (Charles River Laboratories syngeneic mouse models).

Techniques:

KEY RESOURCES TABLE

Journal: Cell reports

Article Title: Fascin inhibitor increases intratumoral dendritic cell activation and anti-cancer immunity

doi: 10.1016/j.celrep.2021.108948

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Moreover, we also studied the mouse neuroendocrine prostate cancer PNEC30 cells that are resistant to ICI treatments (Charles River Laboratories syngeneic mouse models).

Techniques: Control, Recombinant, Plasmid Preparation, shRNA, Membrane